Ketoisdin

Ketoconazole, the active ingredient in Ketoisdin, is an imidazole antifungal presented as a vaginal formulation for local use. It treats vulvovaginal candidiasis in adult women by targeting fungal cells within the vaginal mucosa.

GNH USA supplies Ketoisdin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketoisdin, an imidazole antifungal, is used to treat fungal infections of the vaginal tract.

- Vulvovaginal candidiasis: reduces yeast overgrowth and alleviates associated symptoms such as itching, discharge, and irritation.

Ketoconazole vaginal therapy may cause local and systemic adverse reactions.

Common Side Effects: - Vaginal irritation or burning sensation - Itching at the application site - Increased vaginal discharge - Unpleasant odor - Mild redness or swelling - Dryness of the vaginal mucosa

Serious or Rare Side Effects: - Allergic reaction (rash, hives, swelling) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatotoxicity (rare with topical use) - Systemic hormonal effects - Persistent vaginal ulceration - Secondary bacterial infection

Before using Ketoisdin, consider the following safety measures.

- Confirm diagnosis: Ensure the infection is caused by Candida species. - Pregnancy: Discuss use with a healthcare professional; safety data are limited. - Breastfeeding: Evaluate risk versus benefit with a clinician. - Hepatic impairment: Use with caution in patients with liver disease. - Concomitant topical agents: Avoid applying other vaginal medications simultaneously. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ketoconazole may interact with other medications; monitor accordingly.

Major Interactions (Avoid): - Systemic azole antifungals (e.g., oral fluconazole) – increased risk of toxicity. - CYP3A4 substrates with narrow therapeutic index (e.g., certain statins) – potential for elevated plasma levels.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives – possible reduction in efficacy. - Warfarin – may enhance anticoagulant effect. - Rifampin – may decrease ketoconazole concentrations. - Immunosuppressants (e.g., cyclosporine) – monitor drug levels.